玻璃体内注射贝伐单抗治疗既往球后注射曲安奈德后发生的特发性脉络膜新生血管化。
Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone.
作者信息
Gomi Fumi, Nishida Kentaro, Oshima Yusuke, Sakaguchi Hirokazu, Sawa Miki, Tsujikawa Motokazu, Tano Yasuo
机构信息
Department of Ophthalmology, Osaka University Medical School, Osaka, Japan.
出版信息
Am J Ophthalmol. 2007 Mar;143(3):507-10. doi: 10.1016/j.ajo.2006.10.050. Epub 2006 Dec 8.
PURPOSE
To assess short-term efficacy and safety of intravitreal bevacizumab injections for idiopathic choroidal neovascularization (CNV) refractory to posterior subtenon triamcinolone injections.
DESIGN
Noncomparative, interventional case series.
METHODS
Intravitreal bevacizumab was injected into 10 eyes with idiopathic CNV in which posterior subtenon triamcinolone injections were not efficacious for more than three months. The main outcome measures were changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and fluorescein angiography findings before and after bevacizumab injection.
RESULTS
After treatment, the BCVA improvement at one month (P = .029) continued to three months (P = .003). CRT decreased significantly (P < .001). Leakage from idiopathic CNV three months after treatment stopped in seven eyes, decreased in two, and continued in one. In one patient, conjunctival swelling developed after the injection but resolved and did not recur after another injection. No other complications developed.
CONCLUSIONS
Intravitreal bevacizumab improves BCVA in eyes with idiopathic CNV refractory to triamcinolone.
目的
评估玻璃体内注射贝伐单抗治疗对后Tenon囊下注射曲安奈德无效的特发性脉络膜新生血管（CNV）的短期疗效和安全性。
设计
非对照性干预病例系列。
方法
对10例后Tenon囊下注射曲安奈德超过三个月无效的特发性CNV患者的眼睛进行玻璃体内贝伐单抗注射。主要观察指标为贝伐单抗注射前后最佳矫正视力（BCVA）、中心视网膜厚度（CRT）及荧光素血管造影结果的变化。
结果
治疗后，一个月时BCVA改善（P = 0.029），持续至三个月（P = 0.003）。CRT显著降低（P < 0.001）。治疗三个月后，7只眼特发性CNV渗漏停止，2只眼渗漏减少，1只眼渗漏持续。1例患者注射后出现结膜肿胀，但消退且再次注射后未复发。未出现其他并发症。
结论
玻璃体内注射贝伐单抗可改善对曲安奈德无效的特发性CNV患者眼睛的BCVA。
Zotero 插件